UiPath to Replace Synovus in S&P MidCap 400 Effective January 2, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Should l Buy AGIO?
Source: Benzinga
- Market Position Enhancement: UiPath announced it will replace Synovus Financial Corp. in the S&P MidCap 400 effective January 2, 2026, marking a significant recognition of the company's market position, which is expected to attract more institutional investor interest.
- Stock Price Surge: Following the announcement, UiPath's shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism about its future growth potential, which may further boost investor confidence.
- FDA Drug Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating adult alpha or beta thalassemia, and although its stock fell 1.4% to $24.59, the drug's market entry could open new revenue streams for the company.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% to $18.09 in after-hours trading, demonstrating the company's confidence in its value and potentially enhancing investor retention.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 29.610
Low
25.00
Averages
36.14
High
62.00
Current: 29.610
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Seeks Accelerated Approval for Mitapivat in Sickle Cell Disease
- FDA Review Progress: Agios has submitted a proposal for a confirmatory clinical trial to the FDA for Mitapivat, aimed at supporting its accelerated approval in sickle cell disease, indicating the company's proactive efforts to meet patient needs.
- Clinical Trial Results: The RISE UP Phase 3 trial demonstrated that Mitapivat significantly improved hemoglobin levels compared to placebo, although the annualized rate of pain crises did not reach statistical significance, reflecting the drug's potential clinical value.
- Future Plans: The company plans to submit a supplemental New Drug Application (sNDA) for Mitapivat in the coming months and is actively working with the FDA to align on the confirmatory trial, showcasing its strong commitment to expedited market entry.
- Market Impact: Sickle cell disease is a serious inherited blood disorder, and the successful launch of Mitapivat could provide new treatment options for patients, potentially significantly improving their quality of life and enhancing Agios's market position.
See More
Agios Pharmaceuticals Seeks Accelerated Approval for Pyrukynd Expansion
- Stock Surge: Shares of Agios Pharmaceuticals (AGIO) rose approximately 14% on Tuesday, reflecting market optimism regarding its plans for seeking U.S. accelerated approval, indicating investor confidence in the company's growth potential.
- FDA Recommendation: During a pre-supplemental New Drug Application meeting, the FDA recommended that Agios submit a proposal for a confirmatory clinical trial to support potential accelerated approval for mitapivat in sickle cell disease, showcasing regulatory endorsement of its product.
- Clinical Trial Proposal: Agios has submitted its proposal for the confirmatory trial for regulatory review and plans to submit the sNDA for sickle cell disease in the coming months, demonstrating proactive steps in expanding its product indications.
- Stable Expense Outlook: Despite the initiation of a new clinical trial, Agios noted that its outlook for 2026 operating expenses will remain roughly unchanged, indicating the company's ability to maintain financial stability while expanding its product line.
See More
Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment
- Drug Approval: Agios Pharmaceuticals' PYRUKYND (mitapivat) has been approved by the Emirates Drug Establishment, becoming the only treatment option for adults with non-transfusion-dependent and transfusion-dependent thalassemia in the UAE, marking a significant breakthrough in treatment options.
- Clinical Trial Support: This approval is based on results from the global randomized double-blind ENERGIZE and ENERGIZE-T Phase 3 trials, demonstrating that PYRUKYND can effectively improve hemoglobin levels in patients, addressing the urgent need for innovative therapies in the region.
- Market Potential: With approximately 70,000 individuals affected by thalassemia in the Gulf region, the launch of PYRUKYND is expected to significantly enhance patients' quality of life and provide strong support for Agios's expansion in this market.
- Commercial Partnership: Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to advance regulatory filings and commercialization of PYRUKYND in the Gulf Cooperation Council, further solidifying its strategic position in the Middle East and North Africa market.
See More
Commodore Capital Fully Sells Agios Pharmaceuticals Shares
- Share Sale Details: Commodore Capital disclosed in a SEC filing that it sold all 2,338,287 shares of Agios Pharmaceuticals in Q4 2026, amounting to approximately $93.86 million, indicating a significant loss of confidence in the company.
- Market Performance Analysis: As of February 17, 2026, Agios shares were priced at $27.82, down 17% over the past year, significantly underperforming the S&P 500's roughly 13% gain, reflecting market concerns about its future prospects.
- Financial Overview: Agios Pharmaceuticals has a market capitalization of $1.63 billion, with a trailing twelve-month revenue of $54.03 million and a net loss of $412.78 million, highlighting substantial challenges in achieving profitability.
- Investor Focus: In the biotech sector, capital is shifting towards momentum-driven companies, and Agios's poor performance in clinical trials has led to a sharp stock decline, prompting investors to prioritize execution over mere asset options.
See More
Rock Springs Capital Reduces Agios Holdings
- Share Reduction Details: Rock Springs Capital Management disclosed the sale of 159,379 shares of Agios Pharmaceuticals in Q4 2026, with an estimated transaction value of $5.59 million, indicating a decline in confidence towards the company.
- Position Value Change: As of Q4 2026, Rock Springs' position in Agios was valued at $21.75 million, down $16.72 million from the previous quarter, reflecting negative market sentiment and trading activity impacting the stock.
- Market Performance Analysis: Agios shares were priced at $27.96 as of February 16, 2026, down 16% over the past year and trailing the S&P 500 by 27.8 percentage points, indicating challenges in its competitive position within the biotechnology sector.
- Investor Focus: Despite the reduction in holdings, the FDA approved AQVESME for adult anemia treatment in December 2026, highlighting Agios' potential in rare diseases, prompting investors to monitor future clinical developments closely.
See More
Agios Pharmaceuticals Q4 2025 Earnings Call Insights
- AQVESME Launch Strategy: CEO Brian Goff emphasized that Agios will focus on executing a high-impact launch of AQVESME for thalassemia treatment in the U.S. in 2026, which is expected to enhance the company's market share and lay the groundwork for future expansions.
- PYRUKYND Revenue Growth: In Q4 2025, PYRUKYND net revenue reached $20 million, reflecting an impressive 86% year-on-year growth, indicating the effectiveness of the company's commercialization strategy in the PK deficiency market, with projected revenues of $45 million to $50 million in 2026.
- Strong Financial Position: Agios ended 2025 with approximately $1.2 billion in cash and cash equivalents, providing flexibility for the AQVESME launch and other R&D projects, showcasing the company's confidence and capability in future investments.
- Optimistic Market Outlook: Management expressed optimism regarding early market response for AQVESME, with 44 prescriptions written by REMS-certified physicians as of January 30, reflecting strong recognition of clinical value and expected to drive future revenue growth.
See More
Agios Seeks Accelerated Approval for Mitapivat in Sickle Cell Disease
- FDA Review Progress: Agios has submitted a proposal for a confirmatory clinical trial to the FDA for Mitapivat, aimed at supporting its accelerated approval in sickle cell disease, indicating the company's proactive efforts to meet patient needs.
- Clinical Trial Results: The RISE UP Phase 3 trial demonstrated that Mitapivat significantly improved hemoglobin levels compared to placebo, although the annualized rate of pain crises did not reach statistical significance, reflecting the drug's potential clinical value.
- Future Plans: The company plans to submit a supplemental New Drug Application (sNDA) for Mitapivat in the coming months and is actively working with the FDA to align on the confirmatory trial, showcasing its strong commitment to expedited market entry.
- Market Impact: Sickle cell disease is a serious inherited blood disorder, and the successful launch of Mitapivat could provide new treatment options for patients, potentially significantly improving their quality of life and enhancing Agios's market position.
See More
Agios Pharmaceuticals Seeks Accelerated Approval for Pyrukynd Expansion
- Stock Surge: Shares of Agios Pharmaceuticals (AGIO) rose approximately 14% on Tuesday, reflecting market optimism regarding its plans for seeking U.S. accelerated approval, indicating investor confidence in the company's growth potential.
- FDA Recommendation: During a pre-supplemental New Drug Application meeting, the FDA recommended that Agios submit a proposal for a confirmatory clinical trial to support potential accelerated approval for mitapivat in sickle cell disease, showcasing regulatory endorsement of its product.
- Clinical Trial Proposal: Agios has submitted its proposal for the confirmatory trial for regulatory review and plans to submit the sNDA for sickle cell disease in the coming months, demonstrating proactive steps in expanding its product indications.
- Stable Expense Outlook: Despite the initiation of a new clinical trial, Agios noted that its outlook for 2026 operating expenses will remain roughly unchanged, indicating the company's ability to maintain financial stability while expanding its product line.
See More
Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment
- Drug Approval: Agios Pharmaceuticals' PYRUKYND (mitapivat) has been approved by the Emirates Drug Establishment, becoming the only treatment option for adults with non-transfusion-dependent and transfusion-dependent thalassemia in the UAE, marking a significant breakthrough in treatment options.
- Clinical Trial Support: This approval is based on results from the global randomized double-blind ENERGIZE and ENERGIZE-T Phase 3 trials, demonstrating that PYRUKYND can effectively improve hemoglobin levels in patients, addressing the urgent need for innovative therapies in the region.
- Market Potential: With approximately 70,000 individuals affected by thalassemia in the Gulf region, the launch of PYRUKYND is expected to significantly enhance patients' quality of life and provide strong support for Agios's expansion in this market.
- Commercial Partnership: Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to advance regulatory filings and commercialization of PYRUKYND in the Gulf Cooperation Council, further solidifying its strategic position in the Middle East and North Africa market.
See More
Commodore Capital Fully Sells Agios Pharmaceuticals Shares
- Share Sale Details: Commodore Capital disclosed in a SEC filing that it sold all 2,338,287 shares of Agios Pharmaceuticals in Q4 2026, amounting to approximately $93.86 million, indicating a significant loss of confidence in the company.
- Market Performance Analysis: As of February 17, 2026, Agios shares were priced at $27.82, down 17% over the past year, significantly underperforming the S&P 500's roughly 13% gain, reflecting market concerns about its future prospects.
- Financial Overview: Agios Pharmaceuticals has a market capitalization of $1.63 billion, with a trailing twelve-month revenue of $54.03 million and a net loss of $412.78 million, highlighting substantial challenges in achieving profitability.
- Investor Focus: In the biotech sector, capital is shifting towards momentum-driven companies, and Agios's poor performance in clinical trials has led to a sharp stock decline, prompting investors to prioritize execution over mere asset options.
See More
Rock Springs Capital Reduces Agios Holdings
- Share Reduction Details: Rock Springs Capital Management disclosed the sale of 159,379 shares of Agios Pharmaceuticals in Q4 2026, with an estimated transaction value of $5.59 million, indicating a decline in confidence towards the company.
- Position Value Change: As of Q4 2026, Rock Springs' position in Agios was valued at $21.75 million, down $16.72 million from the previous quarter, reflecting negative market sentiment and trading activity impacting the stock.
- Market Performance Analysis: Agios shares were priced at $27.96 as of February 16, 2026, down 16% over the past year and trailing the S&P 500 by 27.8 percentage points, indicating challenges in its competitive position within the biotechnology sector.
- Investor Focus: Despite the reduction in holdings, the FDA approved AQVESME for adult anemia treatment in December 2026, highlighting Agios' potential in rare diseases, prompting investors to monitor future clinical developments closely.
See More
Agios Pharmaceuticals Q4 2025 Earnings Call Insights
- AQVESME Launch Strategy: CEO Brian Goff emphasized that Agios will focus on executing a high-impact launch of AQVESME for thalassemia treatment in the U.S. in 2026, which is expected to enhance the company's market share and lay the groundwork for future expansions.
- PYRUKYND Revenue Growth: In Q4 2025, PYRUKYND net revenue reached $20 million, reflecting an impressive 86% year-on-year growth, indicating the effectiveness of the company's commercialization strategy in the PK deficiency market, with projected revenues of $45 million to $50 million in 2026.
- Strong Financial Position: Agios ended 2025 with approximately $1.2 billion in cash and cash equivalents, providing flexibility for the AQVESME launch and other R&D projects, showcasing the company's confidence and capability in future investments.
- Optimistic Market Outlook: Management expressed optimism regarding early market response for AQVESME, with 44 prescriptions written by REMS-certified physicians as of January 30, reflecting strong recognition of clinical value and expected to drive future revenue growth.
See More
